Overview
Regulatory capture occurs when a regulatory agency, created to act in the public interest, instead advances the commercial or political concerns of the industry it is supposed to regulate. The FDA presents one of the most documented cases of regulatory capture in the U.S. government.
The agency responsible for ensuring drug safety receives approximately 75% of its drug review budget directly from pharmaceutical company user fees. This funding structure, combined with a well-documented revolving door between the FDA and the pharmaceutical industry, creates systemic conflicts of interest that critics argue compromise public health.
Multiple studies, congressional investigations, and whistleblower testimonies have documented how this arrangement leads to accelerated drug approvals, suppression of negative safety data, and inadequate post-market surveillance.
"The thing that bugs me is that the people think the FDA is protecting them. It isn't. What the FDA is doing and what the public thinks it's doing are as different as night and day."
- Dr. Herbert Ley, Former FDA Commissioner (1969-1970)
Industry Funding Structure
The Prescription Drug User Fee Act (PDUFA) of 1992 fundamentally changed how the FDA operates, creating a direct financial relationship between the agency and the companies it regulates.
User Fee Dependency
Under PDUFA, pharmaceutical companies pay fees to the FDA to review their drug applications. This has grown to represent the majority of the FDA's drug review budget:
- 75% of the FDA's drug review budget comes from industry user fees
- In FY2022, PDUFA fees totaled over $1.1 billion
- Single drug application fees can exceed $3 million
- The FDA must meet performance goals set in negotiations with industry
Performance Goals Problem
PDUFA comes with performance goals negotiated between the FDA and industry every five years:
- Pressure to approve drugs faster, not necessarily safer
- Review times have shortened from an average of 30 months to under 10 months
- Staff evaluated on meeting deadlines rather than safety outcomes
- Accelerated approval pathways have expanded significantly
Financial Conflict
When an agency depends on fees from the companies it regulates, it creates an inherent conflict of interest. The FDA's "customers" have become the pharmaceutical companies rather than the public it is meant to protect.
The Revolving Door
The movement of personnel between the FDA and pharmaceutical industry creates networks of relationships and potential conflicts of interest.
Scott Gottlieb
FDA Commissioner 2017-2019
Former venture partner at a pharmaceutical investment firm. After leaving FDA, joined board of Pfizer and other pharmaceutical companies.
Mark McClellan
FDA Commissioner 2002-2004
After FDA, became director of healthcare policy at American Enterprise Institute, with pharmaceutical industry connections.
Stephen Hahn
FDA Commissioner 2019-2021
After leaving FDA, became chief medical officer at Flagship Pioneering, a life sciences venture capital firm.
Advisory Committee Members
Ongoing Issue
Studies show that advisory committee members with financial conflicts tend to vote in favor of the drugs made by companies paying them.
2016 Science Study Findings
A study published in the British Medical Journal found that of 107 FDA advisers who voted on 28 drug approvals, 40% had financial conflicts of interest. Advisers with conflicts were significantly more likely to vote in favor of the drug.
Fast-Tracked Approvals
Multiple pathways now exist to accelerate drug approval, often based on surrogate endpoints rather than actual clinical outcomes.
Accelerated Approval Pathway
- Created in 1992, originally for serious conditions with unmet needs
- Allows approval based on surrogate endpoints (lab measurements) rather than clinical outcomes (actual health improvement)
- Post-market studies to confirm benefit often delayed or never completed
- From 1992-2021, only 19 drugs were withdrawn through this pathway despite many failing to confirm benefit
Notable Controversial Approvals
Aduhelm (Aducanumab)
Approved for Alzheimer's despite advisory committee voting against it. Three committee members resigned in protest. Clinical trials failed to show cognitive benefit.
Exondys 51 (Eteplirsen)
Approved for Duchenne muscular dystrophy despite review team recommending against approval. No clinical benefit demonstrated.
Accelerated Approval Expansion
FDA Safety and Innovation Act expanded fast-track pathways, further reducing review requirements.
Surrogate Endpoints
A surrogate endpoint is a measurement (like tumor shrinkage or lowered cholesterol) used as a substitute for a clinical endpoint (like survival or reduced heart attacks). Many drugs approved on surrogate endpoints later fail to show actual clinical benefit.
Data Suppression
Multiple mechanisms exist for negative safety and efficacy data to be suppressed or minimized in the drug approval process.
Publication Bias
- Companies are not required to publish all clinical trial results
- Negative trials often go unpublished
- Ghost-writing of journal articles by company employees common
- Selective outcome reporting distorts the evidence base
Whistleblower Testimonies
Dr. David Graham
FDA Safety Officer
Testified before Congress that Vioxx had caused an estimated 88,000-139,000 heart attacks. Said FDA was "incapable of protecting America" against dangerous drugs.
Dr. Ronald Kavanagh
Former FDA Reviewer
Reported being pressured to approve drugs he considered unsafe. Said management told him: "The drug industry is our client."
"As currently configured, the FDA is not able to adequately protect the American public. It's more interested in protecting the interests of industry."
- Dr. David Graham, FDA Safety Officer, Senate Testimony 2004
Documentary Evidence
FDA User Fee Reports
Annual PDUFA financial reports showing industry fee contributions to FDA budget. Available on FDA.gov.
FDA Official RecordsGAO Reports on FDA
Multiple Government Accountability Office reports on FDA drug safety, post-market surveillance, and conflicts of interest.
GAO.govSenate Finance Committee Investigation (2004)
Congressional investigation into FDA handling of Vioxx safety data, including Dr. Graham's testimony.
Congressional RecordBMJ Conflicts of Interest Studies
Peer-reviewed studies examining financial conflicts among FDA advisory committee members.
British Medical Journal